medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-10-44-46medsovet-1404Research ArticleОнкологияOncologyПрименение эритропоэтина тета в лечении анемии у онкологических пациентовAPPLICATION OF ERYTHROPOIETIN THETA IN THERAPY OF ANEMIA IN ONCOLOGIC PATIENTSГЛАДКОВО. А.GLADKOVO. A.

д.м.н.

Челябинск

MD

Chelyabinsk

СНЕГОВОЙА. В.SNEGOVOYA. V.

к.м.н.

Москва

PhD in medicine

Moscow

ООО «ЭВИМЕД»РоссияEVIMED LLCRussian FederationРоссийский онкологический научный центр им. Н.Н. Блохина Минздрава РоссииРоссияBlokhin Russian Oncologic Scientific Center of the Ministry of Health of RussiaRussian Federation2016301220160104446Copyright © ГЛАДКОВ О.А., СНЕГОВОЙ А.В., 20162016ГЛАДКОВ О.А., СНЕГОВОЙ А.В.GLADKOV O.A., SNEGOVOY A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1404

Анемия является одним из часто возникающих осложнений у больных со злокачественными новообразованиями, характеризуется снижением уровня гемоглобина и возникновением нарушения ряда физиологических и метаболических процессов в организме, ухудшая течение болезни и качество жизни пациентов. Основными причинами снижения уровня гемоглобина являются: индукция анемии опухолью, химиотерапией и анемия хронического воспаления. Наиболее частыми методами лечения являются: переливание эритроцитов, назначение эритропоэзстимулирующих агентов (ЭСА) и препаратов железа. Назначение эритропоэтинов представляется более предпочтительным, принимая во внимание осложнения, связанные с проведением гемотрансфузий. Среди ЭСА первого поколения хорошо известными и изученными являются эритропоэтины альфа и бета. Эритропоэтин тета не является биоаналогом: представлен в виде отдельного продукта. В исследованиях показал не меньшую эффективность лечения анемии у онкологических больных в сравнении с используемым эритропоэтином бета. Дозировка 20 000 МЕ эпоэтина тета была достаточной для полного ответа гемоглобина более чем у половины пациентов.

Anemia is one of the most frequent complications arising in patients with malignant growths, it is characterized by reduction of hemoglobin level and disturbance of a number of physiological and metabolic processes in the organism, impairing the course of the disease and patients’ life quality. The major reasons of the hemoglobin concentration reduction include: anemia induction by the tumour, chemotherapy and chronic inflammation anemia. The most frequent methods of therapy are: red blood cell transfusion, prescription of erythropoiesis-stimulating drugs (ESA) and iron supplements. Erythropoietins indication is the most preferential method taking into account complications related to red blood cell transfusions. Erythropoetins alpha and beta are the most well-known and well-studied among the first generation ESAs. The erythropoietin theta is not a biological analogue. It is represented as a separate product. It demonstrated non-inferiority of anemia treatment in cancer patients as compared to the erythropoietin beta in studies. Dosage of 20 000 IU of erythropoietin theta was sufficient for the full hemoglobin response in more than a half of patients.

анемияэритропоэтиныэритропоэтин тетаanemiaerythropoietinserythropoietin thetaReferencesLudwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer, 2004, 40: 2293-2306.Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer, 2004, 40: 2293-2306.Liutkauskiene S, Janciauskiene R, Jureniene K, Grizas S, Malonyte R, Juozaityte E. Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients. BMC Cancer, 2015, 15: 105.Liutkauskiene S, Janciauskiene R, Jureniene K, Grizas S, Malonyte R, Juozaityte E. Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients. BMC Cancer, 2015, 15: 105.Anía B, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ 3rd. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc, 1997, 45(7): 825-31.Anía B, Suman VJ, Fairbanks VF, Rademacher DM, Melton LJ 3rd. Incidence of anemia in older people: an epidemiologic study in a well defined population. J Am Geriatr Soc, 1997, 45(7): 825-31.M. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancerrelated anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol, 2012, 23: 1954-1962.M. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancerrelated anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol, 2012, 23: 1954-1962.Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother, 2013, 40(5): 302-9.Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother, 2013, 40(5): 302-9.Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B and for the Epoetin Alfa Study Group. Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double- Blind, Placebo-Controlled Trial. J Clin Oncol, 2001, 19: 2865-2874.Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B and for the Epoetin Alfa Study Group. Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double- Blind, Placebo-Controlled Trial. J Clin Oncol, 2001, 19: 2865-2874.Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. and For the Aranesp™ 980297 Study Group. Double-Blind, Placebo- Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy. J Natl Cancer Inst, 2001, 94: 1211-1220.Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, et al. and For the Aranesp™ 980297 Study Group. Double-Blind, Placebo- Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy. J Natl Cancer Inst, 2001, 94: 1211-1220.Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst, 2006, 98: 708-714.Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst, 2006, 98: 708-714.Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Kara J et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA, 2008, 299(8): 914-924.Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Kara J et al. Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA, 2008, 299(8): 914-924.Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis- timulating agents in tumor progression. Clin Cancer Res, 2011, 17(20): 6373-80.Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis- timulating agents in tumor progression. Clin Cancer Res, 2011, 17(20): 6373-80.Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al., rythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev, 2012, 12, 12: CD003407.Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al., rythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev, 2012, 12, 12: CD003407.Jelkmann W. Biosimilar epoetins and other «follow-on» biologics: Update on the European experiences. Am J Hematol, 2010, 85(10): 771- 780.Jelkmann W. Biosimilar epoetins and other «follow-on» biologics: Update on the European experiences. Am J Hematol, 2010, 85(10): 771- 780.Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf, 2010 Sep, 3(3): 45-53.Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf, 2010 Sep, 3(3): 45-53.Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf, 2011, 4(3): 33-41.Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial. Arch Drug Inf, 2011, 4(3): 33-41.

The authors declare that there are no conflicts of interest present.